AJKD Atlas of Renal Pathology: Karyomegalic Nephropathy

American Journal of Kidney Diseases AJKD Atlas of Renal Pathology: Karyomegalic Nephropathy

Karyomegalic nephropathy is a rare autosomal recessive disease due to mutation in the FAN1 gene, resulting in low-grade proteinuria and slowly progressive GFR loss starting in the third decade of life, culminating in end-stage kidney disease.


http://www.ajkd.org/article/S0272-6386(16)30114-7/abstract?rss=yes

Sent with Reeder

Enviado desde mi iPhone

Interpreting Anti-HLA Antibody Testing Data: A Practical Guide for Physicians.

Transplantation - Published Ahead-of-Print Interpreting Anti-HLA Antibody Testing Data: A Practical Guide for Physicians.

The development of sensitive methods for alloantibody detection has been a significant advance in clinical transplantation. However, the complexity of the data from solid phase and crossmatch assays has led to potential confusion about how to use the results for clinical decision making. The goal of this review is to provide a practical guide for transplant physicians for the interpretation of antibody data to supplement consultation with local tissue typing experts. Sources of variability in both the solid phase and crossmatch assay are discussed as are recent data regarding C1q binding antibodies and IgG subclass testing. Although definitive approaches to alloantibody testing are not possible with our current knowledge, we outline a pragmatic approach that we hope will enhance clinical management in this area. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.


http://pdfs.journals.lww.com/transplantjournal/9000/00000/Interpreting_Anti_HLA_Antibody_Testing_Data___A.97437.pdf

Sent with Reeder

Alberto Reino Buelvas

Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial

AJT - Early Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial

Abstract

The indication of antimicrobial treatment for asymptomatic bacteriuria (AB) after kidney transplantation (KT) remains controversial. Between January 2011 and December 2013 112 KT recipients that developed ≥1 episode of AB beyond the second month post-transplantation were included in this open-label trial. Participants were randomized (1:1 ratio) to the treatment group (systematic antimicrobial therapy for all episodes of AB occurring up to 24 months post-transplantation [53 patients]) or control group (no antimicrobial therapy [59 patients]). Systematic screening for AB was similarly performed in both groups. The primary outcome was the occurrence of acute pyelonephritis at 24-month follow-up. Secondary outcomes included lower urinary tract infection, acute rejection, Clostridium difficile infection, colonization/infection by multidrug-resistant bacteria, graft function, and all-cause mortality. There were no differences in the primary outcome in the intention-to-treat (7.5% [4/53] in treatment group versus 8.4% [5/59] in control group; odds ratio [OR]: 0.88; 95% confidence interval [CI]: 0.22-3.47) or per-protocol populations (3.8% [1/26] in treatment group versus 8.0% [4/50] in control group; OR: 0.46; 95% CI: 0.05-4.34). We found no differences in any of the secondary outcomes either. In conclusion, systematic screening and treatment of AB beyond the second month after transplantation provide no apparent benefit among KT recipients (NCT02373085).

This article is protected by copyright. All rights reserved.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajt.13829

Sent with Reeder

Alberto Reino Buelvas

¿Qué pasa con las IPS en Colombia?

Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies.

AJT Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies.

• Ferrandiz I, Congy-Jolivet N, Del Bello A, et al. 
• Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies. [JOURNAL ARTICLE]
• Am J Transplant 2016 Mar 21.

Little is known about the impact of post-transplant blood transfusion on the sensitization of anti-HLA antibodies and the formation of donor-specific antibodies (DSAs). The aims of our study were to determine the 1-year incidence of DSAs (assessed using a solid-phase assay) and antibody-mediated rejection (AMR) in kidney-transplant patients who had or had not received a blood transfusion during the first year post-transplantation. Included were 390 non-HLA sensitized patients who had received an ABO-compatible kidney transplant, and had not previously or simultaneously received a non-kidney transplant. Sixty-four percent of patients received a red blood-cell transfusion within the first year post-transplantation, mostly within the first month. The overall 1-year incidence of DSAs was significantly higher in patients that had undergone transfusion (7.2% vs. 0.7% in patients with no transfusion, p<0.0001). AMR occurred more often in the transfusion group (n=15, 6%) compared to the non-transfusion group (n=2, 1.4%), p=0.04. Blood transfusion was an independent predictive factor for de novo DSA formation but not for AMR. Patients who had a transfusion and developed DSAs were more often treated with cyclosporin A (n=10, 55.5%) rather than tacrolimus (n=45, 19.4%), p=0.0001). In conclusion, early post-transplant blood transfusion may increase immunological risk, especially in under-immunosuppressed patients. This article is protected by copyright. All rights reserved.

http://www.unboundmedicine.com/medline/citation/26998676/Impact_of_early_blood_transfusion_after_kidney_transplantation_on_the_incidence_of_donor_specific_anti_HLA_antibodies_

Sent with Reeder

Enviado desde mi iPhone

Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fajt.13795